Randomized Trialhigh evidence
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Lancet (London, England)·July 30, 2026·PMID 42532080
Why it mattersZenagamtide combines GLP-1 and amylin receptor agonism in a single molecule, potentially offering enhanced glycemic control and weight loss beyond current agents. This dose-finding study establishes its efficacy and safety profile, informing future development for type 2 diabetes and possibly obesity.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled